



Used in Lieu of PTO/SB/08A/B  
(Based on PTO 01-08 version)

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/524,394
				Filing Date	December 12, 2005
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1646
				Examiner Name	N/A Ruixiang Li
Sheet	1	of	3	Attorney Docket Number	ALXN-P01-095

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,605,279-B2	08-12-2003	Freeman et al.	
	AB	US-20030232745-A1	12-18-2003	Olson et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code <sup>3</sup> -Number <sup>2</sup> -Kind Code <sup>2</sup> (if known)				
	BA	WO-9828332	07-02-1998	Univ Texas et al.		
	BB	WO-9855508	12-10-1998	Sagami Chem Res et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.96(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
	CA	Amersdorfer et al., <i>Infection and Immunity</i> , 65, pp. 3743-3752 (1997).				
	CB	Andre et al., <i>Journal of Virology</i> , 72(2), pp. 1497-1503 (1998).				
	CC	Baribaud, Frederic, et al., "Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN," <i>Journal of Virology</i> , 75(21), pp. 10281-10289 (2001).				
	CD	Berkower, I., et al., "CHIMERIC HIV-1 ENVELOPE GP120-HEPATITIS B CORE ANTIGEN (HbcAg) FUSION PROTEINS FOR HIV-1 VACCINES," <i>FASEB Journal</i> , 10(6):A1082 (1996).				
	CE	BIOSIS DATABASE, PREV 197866028654 & Kataoka et al., <i>Cancer Research</i> , 38(5), pp. 1202-1207 (1987).				
	CF	Cohen, <i>Science</i> , 287, p. 1567 (2000).				
	CG	Curtis, BM, et al., "Sequence and Expression of a Membrane-Associated C-type Lectin that Exhibits CD4-Independent Binding of Human Immunodeficiency Virus Envelope Glycoprotein GP 120," <i>Proc. Natl. Acad. Sci. USA</i> 89:8356-8360 (1992).				
	CH	Eck J., et al., "Cloning of the Mistletoe Lectin Gene and Characterization of the Recombinant A-Chain," <i>European Journal of Biochemistry</i> , 264:775-784 (1999).				
	CI	Engering, Anneke, et al., "The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells," <i>J. of Immunol.</i> , 168, pp. 2118-2126 (2000).				
	CJ	FDA Approves Second Indication for Monoclonal Antibody, June 28, 1993, printed on November 12, 2004 from <a href="http://www.fda.gov/bbs/topics/ANSWERS/ANS00508.html">http://www.fda.gov/bbs/topics/ANSWERS/ANS00508.html</a> , June 28, 1993.				
	CK	Feinberg, Hadar, et al., "Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and DC-SIGNR," <i>Science</i> , 304, pp. 2162-2166 (2004) (with Supplemental Material).				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.L./

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/524,394
				Filing Date	December 12, 2005
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1646 <del>Ruixiang Li</del>
				Examiner Name	N/A
Sheet	2	of	3	Attorney Docket Number	ALXN-P01-095

		published electronically on the Science website, 6 pgs.).	
CL	Geijtenbeek, et al., "Identification of Different Binding Sites in the Dendritic Cell-Specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1," <i>J. Biol. Chem.</i> , 227(13), pp. 11314-11320 (2002).		
CM	Geijtenbeek, Teunis, B.H., et al., "Identification of DC-SIGN, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses," <i>Cell</i> , 100, pp. 575-585 (2000).		
CN	Geijtenbeek, Teunis, B.H., et al., <i>Cell</i> , 100, pp. 587-597 (2000).		
CO	Gruber, Andreas, et al., "Functional Aspects of Binding of Monoclonal Antibody DCN46 to DC-SIGN on Dendritic Cells," <i>Immunology Letters</i> , 84, pp. 103-108 (2002).		
CP	Harlow and Lane, <i>Antibodies, A Laboratory Manual</i> .		
CQ	Janeway, Charles, A., Jr., et al., <i>Immunobiology</i> , (5th ed.), Garland Publishing, New York, p.691 (2001).		
CR	Knight SC., et al., "Bone Marrow-Derived Dendritic Cells, Infection with Human Immunodeficiency Virus, and Immunopathology," <i>Annual Review Immunology</i> 15:593-615 (1997).		
CS	Manca F. et al., "Dendritic Cells Are Potent Antigen-Presenting Cells for In Vitro Induction of Primary Human CD4+ T-Cell Lines Specific for HIV GP 120," <i>Journal of Acquired Immune Deficiency Syndromes</i> 7:15-23 (1994).		
CT	Package insert for Orthoclone OKT3 Sterile Solution (murmonab-CD3) from Ortho Biotech Products LP, Raritan, NJ, Revised March 2001.		
CU	Pohlmann, Stefan, et al., "DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus," <i>J. of Virology</i> , 75(10), pp. 4664-4672 (2001).		
CV	Product Information for Affinity Purified anti-human CD209 (DC-SIGN) antibody, from eBioscience, printed on January 5, 2004 from <a href="http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm">http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm</a>		
CW	Purified Mouse Anti-Human Monoclonal Antibody, BD PharMingen Technical Data Sheet, BD Biosciences Product Information sheet, Catalog Number 551186, 05/01/01.		
CX	Sequence Alignment of Curtis et al., PNAS 89: 8356-8360 (1992) with SEQ ID NO: 2 from U.S.S.N. 09/719,961.		
CY	Solileux, E.J., et al., "Cutting Edge: DC-SIGN; a Related Gene, DC-SIGNR; and CD23 Form a Cluster on 19p.13," <i>The Journal of Immunology</i> , 165:2937-2942 (2000).		
CZ	Steinbrook, R., "One Step Forward, Two Steps Back - Will There Ever Be an AIDS Vaccine?," <i>N. Engl. J. Med.</i> , 357:2653-2655 (2007).		
CA1	Steinman, <i>Cell</i> , 287, pp. 491-494 (2000).		
CB1	Taken, P.J., et al., "Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody," <i>Blood</i> , 106(4):1278-1285 (2005).		
CC1	Toda, et al., <i>Immunology</i> , 92, pp. 111-117 (1997).		
CD1	Tsunetsugu-Yokota, Y. et al., "Efficient Virus Transmission from Dendritic Cells to CD4+ T Cells in Response to Antigen Depends on Close Contact through Adhesion Molecules," <i>Virology</i> 239:259-268 (1997).		
CE1	Vakeva, Antti, P., et al., "Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion," <i>Circulation</i> , 97, pp. 2259-2267 (1998).		
CF1	Woodle, E.S., et al., <i>Transplantation</i> , 68, pp. 608-616 (1999).		
CG1	Yan et al., "β-Glucan, a "Specific" Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)," <i>The Journal of Immunology</i> , 163(6):3045-3052 (1999).		

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/524,394
				Filing Date	December 12, 2005
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1646
				Examiner Name	N/A Ruixiang Li
Sheet	3	of	3	Attorney Docket Number	ALXN-P01-095

	CH1	Zoetewij, JP. et al., "HIV-Dendritic Cell Interactions Promote Efficient Viral Infection of T Cells," Journal of Biomedical Science 5:253-259 (1998).	
--	-----	---	--

Examiner Signature	/Ruixiang Li/	Date Considered	09/10/2008
-----------------------	---------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.L./